Infertility
Conditions
Interventions
Group A:From the 3rd day of menstrual cycle, a fixed dose of r-hFSH 300IU (Gonal-F, product of Merck, Germany)+r-hLH 150IU (Luveris, product of Merck, Germany) was injected for ovarian stimulation.
Group B:From the 3rd day of menstrual cycle, a fixed dose of r-hFSH 300IU (Gonal-F, a product of Merck, Germany) was injected for ovarian stimulation.
Sponsors
The First Affiliated Hospital of Nanjing Medical University / Jiangsu Provincial Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 34 Years
Inclusion criteria
Inclusion criteria: Subjects meeting Poseidon Group 3 criteria: (1) Age < 35 years old; (2)AFC < 5 or AMH < 1.2 µg /L
Exclusion criteria
Exclusion criteria: (1) Subjects whose previous embryo transfer (ET) failure cycle is = 2; (2) Subjects with a history of repeated pregnancy loss (= 2 miscarriages); (3) Subjects with severe endometriosis (as defined by the American Society of Reproductive Medicine (ASRM) in 1996); (4) Subjects suffering from any disease that cannot tolerate ovarian stimulation, embryo transfer or pregnancy; (5) Subjects with any drug contraindication diseases; (6) Subjects participating in another clinical study at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ongoing pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Follicular Output Rate;Follicle-To-Oocyte Index;fertilization rate;implantation rate;Biochemical pregnancy rate;Clinical pregnancy rate;Live birth rate;Number of oocytes retrieved;number of MII oocytes;Number of transferrable embryos;Number of high-quality embryos;Number of fresh embryo transfers;Serum LH?estradiol and progesterone Level on HCG Day;Endometrial thickness on embryo transfer day;pregnancy loss;ectopic pregnancy;pregnancy complications; | — |
Countries
China
Contacts
Public ContactDiao Feiyang, Wang Jing
The First Affiliated Hospital of Nanjing Medical University / Jiangsu Provincial Hospital
Outcome results
None listed